ABIVAX Société Anonyme (EPA: ABVX)
France
· Delayed Price · Currency is EUR
8.44
+0.24 (2.93%)
Nov 22, 2024, 5:35 PM CET
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 61 employees as of December 31, 2023. The number of employees increased by 37 or 154.17% compared to the previous year.
Employees
61
Change (1Y)
37
Growth (1Y)
154.17%
Revenue / Employee
€145,661
Profits / Employee
€2,861,694
Market Cap
534.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 151,292 |
Ipsen S.A. | 5,325 |
Eurofins Scientific SE | 61,798 |
MedinCell S.A. | 134 |
Eurobio Scientific Société anonyme | 300 |
Inventiva S.A. | 123 |
Nanobiotix S.A. | 102 |
Cegedim SA | 6,582 |
ABIVAX Société Anonyme News
- 7 days ago - Abivax reports liqyuduty position - Seeking Alpha
- 8 days ago - Abivax presents third quarter 2024 key financial information - GlobeNewsWire
- 9 days ago - Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - GlobeNewsWire
- 6 weeks ago - Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewsWire
- 7 weeks ago - Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease - GlobeNewsWire
- 7 weeks ago - Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - GlobeNewsWire
- 2 months ago - Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - GlobeNewsWire
- 2 months ago - Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model - GlobeNewsWire